CDC updates 2005-2006 influenza vaccine recommendations

Author: Carrie A. Morantz, Amber Huntzinger
Date: Oct 15, 2005

Delays in influenza vaccine distribution or vaccine supply shortages have occurred in the United States in three of the past five influenza seasons. In previous years, prioritization was implemented to ensure the availability of vaccine for persons at the highest risk of complications from influenza. The Centers for Disease Control and Prevention (CDC) has released updated recommendations for priority use of trivalent inactivated influenza vaccine (TiV) during the 2005-2006 influenza season. Additional information is available online at

Four manufacturers are expected to provide influenza vaccine during the 20052006 influenza season (see accompanying table). Because of uncertainties about the number of available vaccine doses and the timing of distribution, the CDC recommends that the following groups be given priority to receive TIV until October 24, 2005:

* Persons 65 years and older with or without comorbid conditions

* Persons two to 64 years of age with comorbid conditions

* Children six to 23 months of age

* residents of long-term care facilities

* Pregnant women

* Health care professionals who provide direct patient care

* Household contacts and out-of-home caregivers of children younger than six months

Starting October 24, 2005, all persons will be eligible for vaccination.

The tiered use of prioritization is not recommended for LAIV administration. LAIV may be administered at any time for vaccination of nonpregnant healthy persons five to 49 years of age, including most health care professionals and other persons in close contact with groups at high risk for influenza-related complications.

Influenza Vaccine Manufacturers and Projected Supplyfor 2005-2006 SeasonManufacturer Vaccine FormulationSanofi Pasteur, Inc. Fluzone TIV Multidose vial Single-dose prefilled 0.5-mL syringe or vial Single-dose prefilled 0.25-mL syringeChiron Corp. Fluvirin TIV Multidose vial Single-dose prefilled 0.5-mL syringeGlaxoSmithKline, Inc. Fluarix TIV Single-dose prefilled 0.5-mL syringeMedImmune FluMist LAIV Single-dose nasal Vaccines, Inc. sprayer ContainsManufacturer thimerosal? Age indicationSanofi Pasteur, Inc. Yes 6 months and older No 3 years and older No 6 to 35 monthsChiron Corp. Yes 4 years and older No ([double dagger]) 4 years and olderGlaxoSmithKline, Inc. No ([double dagger]) 18 years and olderMedImmune No Healthy, nonpregnant Vaccines, Inc. persons 5 to 49 years of age ProjectedManufacturer dosesSanofi Pasteur, Inc. 60 million *Chiron Corp. 18 to 26 million ([dagger])GlaxoSmithKline, Inc. 8 millionMedImmune 3 million Vaccines, Inc.TIV = trivalent inactivated influenza vaccine; LAIV = live, attenuatedinfluenza vaccine.*--Sanofi Pasteur, Inc., plans to distribute approximately 6 to8 million of the 60 million projected doses in single-doseprefilled syringes or vials.([dagger])--Chiron Corp. plans to distribute most of its vaccine bythe end of October 2005; the exact timing of distribution was uncertainas of press time. A minimal number of doses of thimerosal-free vaccinemay be available late in the influenza season.([double dagger])--These preparations may contain traces of thimerosal.Adapted from Centers for Disease Control and Prevention. Update:influenza vaccine supply and recommendations for prioritization duringthe 2005-06 influenza season. MMWR Morb Mortal Wkly Rep 2005;554:8850.Accessed online September 17, 2005, at: http:////


COPYRIGHT 2005 American Academy of Family PhysiciansCOPYRIGHT 2005 Gale Group

© 2006,, All Rights Reserved.